Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in...
November 12, 2025 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Advances RPT1G for Myeloid Cancer Patients with Phase 1 Safety Data and IND Approval

RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels.Target engagement data indicate that RPT1G inhibits NAMPT in...
May 13, 2025 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS
December 18, 2024 08:30 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
December 10, 2024 14:10 ET | Source: Remedy Plan Therapeutics

UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
December 10, 2024 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax